Hester Biosciences Reports Mixed Performance in Q2 & H1 FY26; Anticipates Growth in Poultry Healthcare Division

Hester Biosciences Ltd. reported a mixed performance in Q2 and H1 FY26, with a decline in Standalone Divisional Product Sales in India but improved cost control and stability in operations. The Poultry Healthcare Division showed an 18% growth in Q2 and 10% for H1, driven by strong demand for vaccines. The company also received market authorisation for its HON2 vaccine, which strengthens its poultry vaccine portfolio and opens export opportunities. The Animal Healthcare Division experienced a delay in government-led immunisation programmes, but the therapeutic and nutritional segments have remained steady. Hester is focused on introducing targeted solutions in both vaccines and health products for large animals and dairy herds. In petcare, the company is building a presence in key urban markets. Hester Africa and Hester Nepal reported mixed results.